Runners and riders in the Covid vaccine race
Pfizer, AstraZeneca and Moderna have gained approval for their Covid vaccines from the Uk regulator and the jabs are previously currently being rolled out. But what about the other vaccine candidates and how shortly will they arrive to industry?
Our checklist presents a snapshot of what the vaccine landscape seems to be like.
The life sciences industry’s response to the pandemic has been unprecedented both of those in conditions of the speed at which it has designed vaccines and its willingness to collaborate with rivals. That has resulted in 237 potential vaccines, of which 64 are in human scientific trials.
Which is wonderful information as, in the vaccines business there is often no “one particular-size-fits-all” solution, with distinct international locations demanding distinct types of vaccines based mostly on a vary of variables such as local climate, land mass and demography. In other text: there is plenty of space in the industry for far more than one particular vaccine.
Covid vaccines accepted by the Uk
Pfizer/BioNtech
Uk approval date: December 2, 2020
Doses: 2
Efficacy: 90pc +
Sort: mRNA
Doses offered or pre-ordered globally: The whole sum is undisclosed, but we know it has 300m on purchase from the EU and 200m from the US, which, jointly with the Uk, brings the whole to 540m
Doses procured by the Uk: 40m
Manufacturing functionality: Up to 2bn doses this yr
